GLP-1 receptor agonists in comparison with SGLT-2 inhibitors

被引：0
|
作者：
Pavlicek, Vojtech [1 ]
机构：
[1] Kantonsspital Munsterlingen, Med Klin, Endokrinol Diabetol & Klin Ernahrung, Spitalcampus 1, CH-8596 Munsterlingen, Switzerland
来源：
DIABETOLOGE | 2020年 / 16卷 / 05期
关键词：
D O I：
10.1007/s11428-020-00644-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：530 / 531
页数：2
相关论文
共 50 条
  • [21] Efficacy of GLP-1 receptor agonists and SGLT-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
    Azhie, A.
    Gupta, S.
    Misra, S.
    Chen, S.
    Meerasa, A.
    Dash, S.
    Woo, M.
    Bhat, M.
    TRANSPLANTATION, 2022, 106 (8S) : 103 - 103
  • [22] Comparative evaluation of GLP-1 receptor agonists and SGLT-2 inhibitors neuroprotective properties in transient brain ischaemia
    Simanenkova, A.
    Timkina, N.
    Fuks, O.
    Khalzova, A.
    Shimshilashvili, A.
    Timofeeva, V.
    Karonova, T.
    Vlasov, T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 3 - 4
  • [23] Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
    Cignarelli, Angelo
    Genchi, Valentina Annamaria
    Le Grazie, Giulia
    Caruso, Irene
    Marrano, Nicola
    Biondi, Giuseppina
    D'Oria, Rossella
    Sorice, Gian Pio
    Natalicchio, Annalisa
    Perrini, Sebastio
    Laviola, Luigi
    Giorgino, Francesco
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [24] An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
    Kilickap, Mustafa
    Kayikcioglu, Meral
    Tokgozoglu, Lale
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2021, 25 (02): : 61 - +
  • [25] Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
    Georgianos, Panagiotis I.
    Vaios, Vasilios
    Roumeliotis, Stefanos
    Leivaditis, Konstantinos
    Eleftheriadis, Theodoros
    Liakopoulos, Vassilios
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [26] SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Moon, Jun Sung
    Hong, Jun Hwa
    Jung, Yong Jin
    Ferrannini, Ele
    Nauck, Michael A.
    Lim, Soo
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2022, 33 (06): : 424 - 442
  • [27] CHANGES IN 24-HOUR URINE PARAMETERS ASSOCIATED WITH SGLT-2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS
    Hsi, Ryan
    Best, Sara
    Oerline, Mary
    Crivelli, Joseph
    Asplin, John
    Maalouf, Naim
    Hollingsworth, John
    Shahinian, Vahakn
    JOURNAL OF UROLOGY, 2024, 211 (05): : E421 - E422
  • [28] Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Singh, Awadhesh Kumar
    Singh, Ritu
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (06): : 329 - 342
  • [29] Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Vestergaard, Peter
    Bonde, Anders N.
    Fosbol, Emil
    Kober, Lars
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 549 - 556
  • [30] EFFICACY OF GLP-1 RECEPTOR AGONISTS AND SGLT-2 INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES IN LIVER TRANSPLANT RECIPIENTS
    Azhie, Amirhossein
    Gupta, Sarang
    Misra, Shruti
    Chen, Shiyi
    Meerasa, Ameena
    Dash, Satya
    Woo, Minna
    Bhat, Mamatha
    GASTROENTEROLOGY, 2022, 162 (07) : S753 - S753
12345